Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
129 hedge funds and large institutions have $1.09B invested in Aegerion Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 51 increasing their positions, 41 reducing their positions, and 29 closing their positions.
25% more call options, than puts
Call options by funds: $29.8M | Put options by funds: $23.9M
24% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 41
7% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 29
2% less funds holding
Funds holding: 131 → 129 (-2)
29% less capital invested
Capital invested by funds: $1.54B → $1.09B (-$446M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$108M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$57.6M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$55.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$20M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$18.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$125M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$49M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$43.1M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$35M |
| 5 |
PC
PointState Capital
New York
|
-$25.1M |
AEGR Hedge Fund Activity: Q2 2014 in Review
129 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q2 2014, worth a combined $1.09B — down 29% from $1.54B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of AEGR and 27 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 51 added.
The largest buyer was Scopia Capital Management, opening a new position worth an estimated $108M. The largest seller was T. Rowe Price Associates, cutting an estimated $125M.
- 129 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q2 2014, down from 131 in Q1 2014.
- Funds reported $1.09B of Aegerion Pharmaceuticals stock for Q2 2014, down 29% quarter-over-quarter.
- 27 funds opened new Aegerion Pharmaceuticals positions in Q2 2014 and 29 closed out, a net change of -2 holders.
- The largest Aegerion Pharmaceuticals buyer in Q2 2014 was Scopia Capital Management, an estimated $108M added.
- The largest Aegerion Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $125M sold.
Based on aggregated 13F filings for Q2 2014.